Kira Downey
Research Interests:
Oncology, neuro-immunology, lymphoid homing, CAR T-cells
Other Interests:
Cooking adventurously, literature, yoga, exploring foreign countries
Email: kira.downey@ucsf.edu
B.A. Macalester College 2016
Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy.
Chuntova P, Downey KM, Hegde B, Almeida ND, Okada H.
Front Immunol. 2019 Jan 22;9:3062. doi: 10.3389/fimmu.2018.03062. eCollection 2018. Review.
Immunotherapy Response Assessment in Neuro-Oncology (iRANO).
Okada H, Downey KM, Reardon D.
Newton HB, ed. Handbook of Brain Tumor Chemotherapy, Molecular Therapeutics, and Immunotherapy, Second Edition. San Diego: Academic Press, 2018: 761-765.
Challenges and Next Steps for CAR T-Cell Therapy for Glioblastoma.
Watchmaker PB, Chuntova P, Downey KM, Chheda ZS, Shahin M, Carrera DA, Okada H.
World Federation of Neuro-Oncology Societies Magazine. June 2018, 3(1):3-13. 3.
Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy.
Chheda ZS, Kohanbash G, Okada K, Jahan N, Sidney J, Pecoraro M, Yang X, Carrera DA, Downey KM, Shrivastav S, Liu S, Lin Y, Lagisetti C, Chuntova P, Watchmaker PB, Mueller S, Pollack IF, Rajalingam R, Carcaboso AM, Mann M, Sette A, Garcia KC, Hou Y, Okada H.
J Exp Med. 2018 Jan 2;215(1):141-157.
Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.
Kohanbash G, Carrera DA, Shrivastav S, Ahn BJ, Jahan N, Mazor T, Chheda ZS, Downey KM, Watchmaker PB, Beppler C, Warta R, Amankulor NA, Herold-Mende C, Costello JF, Okada H.
J Clin Invest. 2017 Apr 3;127(4):1425-1437.